Antimicrobials are substance that kills microorganisms such as bacteria or mold, or stops them from growing and causing disease.
A new study using antimicrobial susceptibility testing and whole genome sequencing to test extended spectrum beta lactamase producing E. coli isolated from cattle for food production and from various retail meat products has shown that all were resistant to at least three antimicrobial classes.
Neem Biotech recently attended the Royal College of Physicians’ Innovation in Medicine Conference 2018 where Neem presented their data around wound-relevant biofilms.
Neem are working on a novel approach to antimicrobial resistance, which involves preventing the formation of and disrupts mature biofilms that are produced by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus.
New data from a study led by researchers from the University of Minnesota Medical School could change how future antimicrobial drug combinations are discovered and developed.
Neem Biotech, a Wales-based R&D biotech working in the field of novel antimicrobial drug development, announced today that it will be presenting results of its ongoing development work into the impact of NX-AS-401, its lead candidate,on biofilms in chronic cystic fibrosis lung infections at the 15th European Cystic Fibrosis Basic Science Conference taking place from 21st to 24th March 2018 in LoutrakiKorinthias, Greece.
An international research team led by the Institute of Bioengineering and Nanotechnology of the Agency for Science, Technology and Research and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects.
WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries.
Patients with bloodstream infections could avoid treatment with a combination of antimicrobial therapies if they are given the right drug as early as possible and if they are classified as at low risk of death.
A state-of-the-art research centre to help accelerate the development of new antibiotics is set to be established by the University of Liverpool.
There has been much recent talk about how to target the rising tide of antibiotic resistance across the world, one of the biggest threats to global health today.
Experts at the European Committee on Antimicrobial Susceptibility Testing, who define the optimal drug concentrations to inhibit the growth of pathogens, have found that genetic methods cannot yet be used to test for susceptibility in a number of important bacterial species.
The U.S. Food and Drug Administration is requesting a total budget of $5.1 billion to protect and promote the public health as part of the President's fiscal year (FY) 2017 budget – an eight percent increase over the enacted budget for FY 2016.
The University of Leicester has been awarded over £1.5 million in order to advance knowledge and understanding in three key areas that impact on health.
The California Veterinary Medical Association (CVMA) applauds Governor Jerry Brown for signing SB 27 (Hill) into law. This bill sets aggressive, groundbreaking standards for antimicrobial drug use in California livestock and will positively impact antibiotic resistance in both humans and animals.
Australian researchers from The University of Queensland have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Borrelidin is a naturally occurring antibiotic isolated from the Streptomyces species and initially from Streptomyces rochei in 1949. It is called Borrelidin because it was firstly discovered as having anti-Borrelia activity. Borrelia is a type of bacteria...
The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) has been joined by the World Health Organisation (WHO) to launch the 7th annual ‘International Day for Fighting Infection’ (April 24th, 2015).
A one-day prevalence survey of 183 hospitals found that approximately 50 percent of hospitalized patients included in the survey were receiving antimicrobial drugs, and that about half of these patients were receiving 2 or more antimicrobial drugs, according to a study in the October 8 JAMA, a theme issue on infectious disease. Most antimicrobial use was for infection treatment.
TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA.
The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.